Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Anavex Life Sciences reports stable finances and promising clinical advancements

Anavex Life Sciences showcased financial stability, positive clinical trial outcomes, and a commitment to advancing treatments for neurological disorders.
While facing challenges in managing net losses and regulatory processes, the company remains well-positioned to capitalize on opportunities for growth and innovation.
Investors can be optimistic about Anavex's progress in developing potential treatments for Alzheimer's disease and schizophrenia, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities' Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT.

Anavex Life Sciences to Present at the B. Riley Securities' Virtual Neuroscience Conference

Axsome Therapeutics

Biogen

Jazz Pharmaceuticals

Cassava Sciences Inc

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Alzheimer's Disease: 5 Stocks on Biotech Radars

Prothena

3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 8:45 a.m. EDT.

Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Establishing Mutually Beneficial Collaborations,” at the World EPA Congress 2021 event on Thursday, April 15t h at 8:55 a.m. EDT (14:55 CET).

Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021

Anavex is targeting Alzheimer's disease and other neurodegenerative diseases. It recently announced positive data from two of its programs.

Anavex: Small Company Targeting The Holy Grail Of Medicine

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Independent Data Safety Monitoring Board (DSMB) for the Company's Phase 2b/3 Alzheimer's disease study of its investigational compound ANAVEX®2-73 (blarcamesine) has completed its recent pre-planned review of the preliminary Phase 2b/3 study data.

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer's Disease

Cassava Sciences simufilam produced an improvement in ADAS-cog scores of 1.6 points at 6 months.

Anavex And Cassava Sciences: Closer To An Understanding Of Alzheimer's Disease

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021.

Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

Denny's

Cloudflare

GoDaddy

Shopify

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Shopify & GoDaddy

Top Wall Street analysts say buy stocks like Denny's and Cloudflare as economy reopens

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, has been invited to present at the 10 th Annual SVB Leerink Global Healthcare Conference.

Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2021 Results - Earnings Call Transcript

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook

Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

Anavex Life Sciences (AVXL) stock is soaring higher Thursday on heavy trading despite a lack of news concerning the company. The post AVXL Stock: 6 Things for Investors to Know About Anavex Life Sciences appeared first on InvestorPlace.

AVXL Stock: 6 Things for Investors to Know About Anavex Life Sciences

The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) is trading at over 60% pre-market today as of 6:04 AM ET. This is why it happened.

AVXL Stock Price Increases Over 60% Pre-Market: Why It Happened

Hologic

Moderna

Novavax

Meridian Bioscience

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Bonanza: COVID Launches Science at Warp Speed

Biohaven Pharmaceutical Hld

Eli Lilly

Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.

Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why

Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Ladenburg Thalmann & Co. will host a webinar at 3:30p.m. Eastern Time on Tuesday, December 22nd, 2020 highlighting Rett Syndrome and ANAVEX®2-73 (blarcamesine) Phase 2 data as part of Ladenburg Thalmann's LT Healthcare Symposia Series.

News for Anavex Life Sciences Stock (AVXL)